Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Faslodex|BIOLOGICAL: Herceptin
Sponsor: Translational Oncology Research International
Collaborators: University of California, Los Angeles|Genentech, Inc.|AstraZeneca